HLS Therapeutics Inc
TSX:HLS
HLS Therapeutics Inc
TSX:HLS
Price:
4.5
CAD
Market Cap:
CA$140.7m
Relative Value
The Relative Value of one
HLS
stock under the Base Case scenario is
5.48
CAD.
Compared to the current market price of 4.5 CAD,
HLS Therapeutics Inc
is
Undervalued by 18%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
HLS
Relative Value
Base Case
5.48
CAD
Undervaluation 18%
Multiples Across Competitors
HLS Competitors Multiples
HLS Therapeutics Inc Competitors
HLS Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
|
HLS Therapeutics Inc
TSX:HLS
|
140.7m CAD | 1.8 | -7.3 | 8.9 | -24.2 | |
| US |
|
Mckesson Corp
NYSE:MCK
|
119.4B USD | 0.3 | 29.6 | 20.8 | 23.4 | |
| US |
|
Cencora Inc
NYSE:COR
|
70.7B USD | 0.2 | 45.3 | 15.3 | 19.7 | |
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
70.5B USD | 0.2 | 45.4 | 15.3 | 19.7 | |
| US |
|
Cardinal Health Inc
NYSE:CAH
|
53.4B USD | 0.2 | 32.1 | 15.4 | 20 | |
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
35.5B AUD | 5.9 | 67 | 50.5 | 50.5 | |
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
9.5B USD | 0.7 | 24.4 | 11.6 | 16.2 | |
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
64.2B CNY | 1.5 | 17.4 | 13.4 | 13.4 | |
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
64.1B CNY | 0.2 | 11.4 | 15.2 | 15.2 | |
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
66.2B HKD | 0.1 | 8.6 | 1.6 | 2 | |
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | 5.9 | 89.6 | 59.9 | 61.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
